ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Analyst Ratings
NASDAQ:ALNY • US02043Q1076
331.015 USD
-5.18 (-1.54%)
Last: Feb 23, 2026, 12:46 PM
ChartMill assigns a Buy % Consensus number of 79% to ALNY. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 482.54. This target is 45.78% above the current price.
- ALNY was analyzed by 36 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ALNY.
- In the previous month the buy percentage consensus was at a similar level.
- ALNY was analyzed by 36 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-17 | Freedom Capital Markets | Upgrade | Hold -> Buy |
| 2026-02-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-12 | Needham | Maintains | Buy -> Buy |
| 2026-01-30 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-20 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-12 | Needham | Maintains | Buy -> Buy |
| 2026-01-12 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-15 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-11-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-31 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-31 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-30 | Jefferies | Maintains | Buy -> Buy |
| 2025-10-17 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-06 | Stifel | Maintains | Buy -> Buy |
| 2025-10-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-11 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-08 | BMO Capital | Maintains | Outperform -> Outperform |
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the average price target for ALNYLAM PHARMACEUTICALS INC stock?
36 analysts have analysed ALNY and the average price target is 482.54 USD. This implies a price increase of 45.78% is expected in the next year compared to the current price of 331.015.
What is the consensus rating for ALNY stock?
The consensus rating for ALNYLAM PHARMACEUTICALS INC (ALNY) is 79.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.